Psychological distress and adaptational problems associated with benzodiazepine withdrawal and outcome: A replication
Introduction
Research in the benzodiazepine (BZD) field points to the influence of psychological factors on withdrawal difficulties and relapse Bélanger et al., 1999, Murphy & Tyrer, 1991, O'Connor et al., 1999, Rickels et al., 1990, Rickels et al., 1986, Schweizer et al., 1990, Schweizer et al., 1998, Tyrer et al., 1983. Psychological differences might explain why some patients do and others do not experience difficulties stopping BZDs, but empirical support on the influence of psychological factors is still scarce. A previous study (O'Connor et al., 1999) examined psychological distress and adaptational problems associated with the discontinuation of BZD. A profile of those likely to experience psychological distress emerged from a multiple regression and correspondence analysis (CA), which indicated that participants with higher neuroticism, higher negative life events, lower quality of life, lower education level, and younger age group clustered together, with a higher reported level of distress.
This previous study (O'Connor et al., 1999) used a cross-sectional design, with measures taken at one point in time, calculated to capture the maximum effect of withdrawal, 2–14 days after cessation. The present study aimed to replicate and extend these previous findings by administering the same psychosocial measures to a group of patients before, during, and after BZD withdrawal. We hypothesized that the same profile of psychosocial measures that had previously characterized psychological distress would, also, in the current study be associated with poorer outcome and greater severity of withdrawal symptoms.
Section snippets
Method
Forty-one participants receiving maintenance BZD therapy for at least 8 weeks, who wished to discontinue BZD use, entered the trial. The patients were all recruited either through clinician referrals or adverts in local media. After a telephone screening, patients were referred for ADIS-IV evaluation, administered by collaborating psychiatrists. The patients had to meet the following criteria: (1) be aged between 18 and 65 years old; (2) be using BZDs as an anxiolytic or hypnotic drug regularly
Analysis
Univariate analyses were performed to assess the impact of the sociodemographic, pharmacological, and psychological variables on the end-point measures. Differences between the success and failure groups and between the two and less and the three and more BWSQ withdrawal complaint groups were assessed through proportion comparisons using chi-square test, or Fisher's Exact Test when needed, one-way analysis of variance, or comparisons of means using unpaired Student t tests, adjusted for
Results
Analysis was conducted on 41 participants, of whom 8 abandoned. Unfortunately, follow-up data were, by definition, not available on those who abandoned, hence, further quantitative analysis was completed on 33 participants in each group. Those who abandoned were less likely to be married (14.3% vs. 66.7%; P<.04). There was a nonsignificant (P<.06) tendency for those who abandoned to be taking more short- than long-acting BZD. Among the 8 who abandoned, 7 were taking short-acting medication.
Discussion
The results replicated the relationship previously reported between psychosocial factors and psychological distress during discontinuation (O'Connor et al., 1999). The profiles of baseline measures characterizing the high levels of psychological distress in the first study were similarly associated with the psychological distress in the current study, that is, low quality of life, low social support, high neuroticism, and high behavioural inhibition. Furthermore, low levels of psychological
References (22)
Anxiolytic drugs: Dependence, addiction and abuse. Symposium: New perspectives in the treatment of anxiety disorders (1993, Oostende, Belgium)
European Neuropsychopharmacology
(1994)- et al.
Psychological distress and adaptational problems experienced during discontinuation of benzodiazepines
Addictive Behaviors
(1999) - et al.
Gradual withdrawal of diazepam after long term therapy
Lancet
(1983) - et al.
The benzodiazepine withdrawal symptom questionnaire
Journal of Affective Disorders
(1990) Adverse effects of prolonged benzodiazepine use
Adverse Drug Reaction Bulletin
(1986)- et al.
Aspects psychologiques de la dépendance aux benzodiazépines
Revue Francophone de Clinique Comportementale et Cognitive
(1999) - et al.
Les Benzodiazépines dans le traitement de la pathologie anxieuse: Indications
Perspectives Psychiatriques
(1992) Benzodiazepine dependence and withdrawal symptoms
Current Problems
(1988)- et al.
Self-efficacy and relapse in smoking cessation programs
Journal of Consulting and Clinical Psychology
(1981) - et al.
A new approach for quality of life assessment in cardiac patients: Rationale and validation of the quality of life systemic inventory
Canadian Journal of Cardiology
(1994)
Manual of the Eysenck personality questionnaire
Cited by (35)
Psychological predictors of benzodiazepine discontinuation among older adults: Results from the PASSE 60+
2020, Addictive BehaviorsCitation Excerpt :This program is designed to facilitate discontinuation of BZD in older people. It was inspired by a previous program developed and validated in adults (O’Connor et al., 2006; O'Connor et al., 2004; O'Connor et al., 2008). It lasts 16 weeks and is composed of 12 cognitive-behavioral therapy (CBT) sessions.
Hans Eysenck and the Individual Differences Paradigm in the clinical setting
2016, Personality and Individual DifferencesClusters of personality traits and psychological symptoms associated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study
2013, Addictive BehaviorsCitation Excerpt :A cross-sectional study of 118 BZ users found that neuroticism and introversion were related to long-term use (Nicholas & Hammond, 1992). Short-term prospective studies have demonstrated that people with combined high neuroticism and introversion report stronger withdrawal symptoms during BZ discontinuation than individuals with low scores on these personality traits (O'Connor et al., 2004; Schweizer, Rickels, De Martins, Case, & Espana-Garcia, 1998). However, the predisposing role of personality traits in regards to later BZ use is unclear as even some cross-sectional studies reported relatively weak associations between personality traits and BZ use (Dåderman & Edman, 2001; Manthey et al., 2011).
Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal
2013, European PsychiatryCitation Excerpt :Many of these are reported anecdotally and few case series exist. High levels of neuroticism, lower educational level and lower quality of life were associated with higher levels of distress during withdrawal [121], and with higher doses, and low levels of social support [122]. A recent prospective study revealed four patterns of withdrawal symptoms over time [177]: a gradual decrease over the 50-week time period; an increase in the severity of symptoms at the onset of tapering and a decrease in severity post-tapering; an increase in the severity of symptoms 4 weeks after the cessation of BZD tapering; no symptoms detectable.
High dose benzodiazepine dependence: Description of 29 patients treated with flumazenil infusion and stabilised with clonazepam
2012, Psychiatry ResearchCitation Excerpt :Retention in treatment with flumazenil is apparently more favourable compared to other methods of abrupt withdrawal using other medications such as propanolol, buspirone and hydroxizine (Lader and Olajide, 1987; Cantopher et al., 1990; Lemoine et al., 1997). The severity of BZD withdrawal may be a consequence of: i) dose of BZD pre-treatment (Rickels et al., 1983; Roy-Byrne and Hommer, 1988); ii) pre-treatment duration of BZD (Griffiths et al., 1993); iii) the half-life of BZD (the withdrawal symptoms tend to be more severe with shorter half-life BZDs) (O'Brien, 2005; Rosenbaum, 2005); iv) dose and rate of flumazenil infusion (Gerra et al., 2002); and v) psychiatric comorbidity and the context in which BZD is used (Bernik et al., 1998; Brady et al., 2003; O'Connor et al., 2004; Ashton, 2005). Given that the small sample size gave limited power to detect differences, no statistical analysis was performed to analyse the factors which may have exacerbated withdrawal symptoms in subjects whose infusion was stopped, compared with those whose infusion continued.